On June 9, local time in the US, MSD announced that the world's first oral PCSK9 inhibitor developed by the company reached a major end in both phase III clinical trials. The company says the drug significantly reduces LDL cholesterol levels compared to placebo and other oral fistatin medications.

On June 9, local time in the US, MSD announced that the world's first oral PCSK9 inhibitor developed by the company reached a major end in both phase III clinical trials. The company says the drug significantly reduces LDL cholesterol levels compared to placebo and other oral fistatin medications.